Median Technologies (ALMDT.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Median Technologies is a dual-platform oncology company that transforms medical images into actionable insights for drug development and patient care. Its core achievements include building a profitable Imaging Lab service business supporting over 220 clinical trials and securing FDA 510(k) clearance for its flagship eyonis® LCS device for lung cancer screening. The company's strategy is to leverage its unique clinical expertise and AI platform to become a leader in AI-powered oncology diagnostics while scaling its high-margin imaging services globally.

Oncology

Technology Platform

A proprietary AI, computer vision, and signal processing platform designed to extract clinical insights from medical images, applied across both diagnostic software (eyonis® SaMD) and imaging services for oncology trials.

Opportunities

The massive, under-penetrated lung cancer screening market in the US and EU represents an immediate multi-billion dollar opportunity for eyonis® LCS.

Furthermore, the expansion of the eyonis® platform into liver disease and other high-burden cancers offers a long-term pipeline for sustained growth, while the Imaging Lab service can capitalize on the increasing complexity and data demands of oncology drug development.

Risk Factors

Key risks include the challenge of commercializing a newly FDA-cleared device in a competitive AI diagnostics market, securing reimbursement, and the capital intensity of scaling the SaMD business while advancing the pipeline.

Technological obsolescence and slower-than-expected adoption by radiologists are additional execution risks.

Competitive Landscape

In AI diagnostics, Median faces intense competition from pure-play AI startups and large imaging OEMs, but differentiates with its integrated CADe/CADx approach and clinical trial pedigree. In imaging services, it competes with large CROs and specialized imaging labs, differentiating through its oncology focus and AI-powered analytics (Imaging Lab).

More companies in AI / Machine Learning →More companies in France →